Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.

Abstract

Cutaneous leishmaniasis poses a therapeutic challenge in the paediatric population. The aim of this study was to assess the efficacy and safety of miltefosine treatment for Old World cutaneous leishmaniasis in paediatric patients. A multicentre retrospective review of 10 children (≤ 18 years of age) with cutaneous leishmaniasis treated with miltefosine in Israel was performed. Mean ± standard deviation age at diagnosis was 9.1 ± 5.0 years. The Leishmania species diagnosed was L. tropica in 8 cases and Leishmania major in 2 cases. Mean ± standard deviation duration of treatment was 44.8 ± 20.6 days, with a mean follow-up period of 12.1 ± 17.1 months. Complete response was noted in 8 (80%) patients. Treatment failure was noted in 2 (20%) cases. Side-effects related to the medication were minimal. In conclusion, oral miltefosine may be an effective and safe treatment for Old World cutaneous leishmaniasis caused by Leishmania tropica or Leishmania major in children. However, further studies are warranted to draw a definite conclusion.

• Authors: Ayelet Ollech, Michal Solomon, Amir Horev, Shiran Reiss-Huss, Dan Ben-Amitai, Alex Zvulunov, Rivka Friedland, Vered Atar-Snir, Vered Molho-Pessach, Aviv Barzilai, Shoshana Greenberger
• Journal: Acta dermato-venereologica (Acta Derm Venereol) Vol. 100 Issue 18 Pg. adv00322 (10 19 2020) ISSN: 1651-2057 [Electronic] Sweden
• PMID: 33074340 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Antiprotozoal Agents
• Phosphorylcholine
• miltefosine

Topics

• Adolescent
• Antiprotozoal Agents (adverse effects)
• Child
• Child, Preschool
• Humans
• Israel
• Leishmaniasis, Cutaneous (diagnosis, drug therapy)
• Phosphorylcholine (adverse effects, analogs & derivatives)
• Retrospective Studies